LCG
SMMT icon

Lisanti Capital Growth’s Summit Therapeutics SMMT Stock Holding History

Lisanti Capital Growth’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-53,850
Closed -$1.04M – 141
2025
Q1 		$1.04M Buy
+53,850
New +$1.08M 0.31% 94

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Lisanti Capital Growth's SMMT Position: Q2 2025 in Review

Lisanti Capital Growth sold out of Summit Therapeutics (SMMT) in Q2 2025, closing a stake of 53,850 shares — an estimated $1.04M sold.

Lisanti Capital Growth first reported a position in SMMT in Q1 2025 and held it in 1 quarter. The position peaked at $1.04M in Q1 2025. 238 funds tracked by Wall St. Rank hold SMMT as of Q2 2025.

  • Lisanti Capital Growth reported no remaining Summit Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Lisanti Capital Growth sold 53,850 Summit Therapeutics shares in Q2 2025, an estimated $1.04M.
  • Lisanti Capital Growth first reported a position in Summit Therapeutics in Q1 2025 and held it in 1 quarter.
  • Lisanti Capital Growth's Summit Therapeutics position peaked at $1.04M in Q1 2025.
  • 238 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2025.

Based on Lisanti Capital Growth's 13F filing for Q2 2025, filed 7 Aug 2025.